Rapidly progressive glomerulonephritis secondary prevention

Revision as of 17:59, 29 May 2018 by Aelsaiey (talk | contribs) (→‎Overview)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Rapidly progressive glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Rapidly progressive glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray Findings

CT-scan Findings

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Rapidly progressive glomerulonephritis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rapidly progressive glomerulonephritis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rapidly progressive glomerulonephritis secondary prevention

CDC on Rapidly progressive glomerulonephritis secondary prevention

Rapidly progressive glomerulonephritis secondary prevention in the news

Blogs on Rapidly progressive glomerulonephritis secondary prevention

Directions to Hospitals Treating Rapidly progressive glomerulonephritis

Risk calculators and risk factors for Rapidly progressive glomerulonephritis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Effective measures for the secondary prevention of rapidly progressive glomerulonephritis include patient education. Patients should be educated about the signs and symptoms of renal dysfunction as certain steroid and immunosuppressive therapy may have adverse effects on the kidneys. Patients should be monitored regularly for renal function and those with severe dysfunction should have be referred for dialysis.

Secondary Prevention

Effective measures for the secondary prevention of rapidly progressive glomerulonephritis include:[1][2][3][4]

  • Patient education: Patient education is an important aspect in early diagnosis and management of rapidly progressive glomerulonephritis.
    • Patients should be educated about the signs and symptoms of renal dysfunction as certain steroid and immunosuppressive therapy may have adverse effects on the kidneys.
    • Patients should be monitored regularly for renal function and dose adjustment of medications.
    • Patients with severe renal dysfunction require long term dialysis and should be advised to seek medical care on a timely basis.
    • Patients with deteriorating renal function despite maximal medical therapy should be put on renal transplantation list and patients should be informed that Goodpasture syndrome may even recur in the transplanted kidney, although it is very rare.

References

  1. Kluth DC, Rees AJ (November 1999). "Anti-glomerular basement membrane disease". J. Am. Soc. Nephrol. 10 (11): 2446–53. PMID 10541306.
  2. Menn-Josephy H, Beck LH (2015). "Recurrent glomerular disease in the kidney allograft". Front Biosci (Elite Ed). 7: 135–48. PMID 25553369.
  3. "Notice". Kidney Int Suppl (2011). 2 (2): 139. 2012. doi:10.1038/kisup.2012.9. PMC 4089568. PMID 25028634.
  4. Chen M, Kallenberg CG (2010). "ANCA-associated vasculitides--advances in pathogenesis and treatment". Nat Rev Rheumatol. 6 (11): 653–64. doi:10.1038/nrrheum.2010.158. PMID 20924413.

Template:WH Template:WS